Effects of ibuprofen on the in vitro invasiveness of a human transitional cell carcinoma

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 365-368

  Cook, Gregory P ^a   Hampton, James A ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Bladder; Carcinoma; Invasion; Nonsteroidal anti inflammatory; Transitional cell

Indexed keywords

IBUPROFEN; MATRIGEL; POLYCARBONATE; PROSTAGLANDIN E2;

ARTICLE; BLADDER CARCINOMA; CANCER INVASION; CELL DIVISION; CELL MOTILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FILTER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARCINOMA, TRANSITIONAL CELL; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IBUPROFEN; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 0031059193     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Catalona WJ: Urothelial tumors of the urinary tract. In: Campbell's Urology. Edited by PC Walsh, AB Retik, TA Stamey, and ED Vaughn, Jr Philadelphia, WB Saunders Co, pp. 1109-1158, 1992.
2. Herr HW, Laudone VP and Badalamen RA: Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 6: 1450-1455, 1988.
3. Nadler, RB, Catalona, WJ and Hudson, MA: Durability of tumor-free response for intravesical Bacillus Calmette-Guerin therapy. J Urol. 156: 367-373, 1994.
4. Schwalb DM, Herr HW, Sogani PC, Russo P, Sheinfeld J and Fair WR: Positive urinary cytology following complete response to intravesical Bacillus CalmetteGuerintherapy: patternofrecurrence. J Urol 152: 382-387, 1994.
5. Kroft SH and Oyasu R: Urinary bladder cancer: Mechanisms of development and progression. Lab Invest 71: 158-174, 1994.
6. Royer GL, Seckman, CE and Welshman IR: Safety profile: fifteen years of clinical experience with ibuprofen. Am J Med 77: 25-34, 1984.
7. Slaton J, Hampton, JA and Selman SH: Exposure to alkyllysophospholipids inhibits in vitro invasion to transitional cell carcinoma. J Urol 152: 1594-1598, 1994.
8. Young MRI, Young ME, Lozano Y and Bagash JM: Activation of protein kinase A increases the in vitro invasion, migration, and adherence to reconstituted basement membrane by Lewis lung carcinoma tumor cells. Invasion Metastasis 12: 253-263, 1992.
9. Gad SC and Weil CS: Statistics and Experimental Design for Toxicologists. Caldwell, NJ: The Telford Press, 1986.
10. Bouchard L and Castonguay A: Inhibitory effects on nonsteroidal anti-inflammatory drugs (NSAIDs) on the metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in mouse lung explants. Drug Metab Dispos 21: 293-298, 1993.
11. Jalbert G and Castonguay A: Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J Mice. CancerLett 66: 21-28, 1992.
12. Wargovich MJ, Harris C, Chen CD, Palmer C, Steele VE and Kelloff GJ: Growth kinetics and chemoprevention of aberrant crypts in the rat colon. J Cell Biochem Suppl 16G: 51-54, 1992.
13. Earnest D, Hixson LJ and Alberts, DS: Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J Cell Biochem Suppl 161: 156-166, 1992.
14. Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G and Reddy BS: Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, -adifluoromethylornithine, 16-a-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 51: 4528-4534, 1991.
15. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V and Reddy BS: Chemoprevention of colon carcinogenesis by Sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 55: 1464-1472, 1995.
16. Boone C, Steele VE and Kelloff GJ: Screening for chemopreventive (anticarcinogenic) compounds in rodents. Mutat Res 267: 251-255, 1992.
17. Shibata M-A, Hasegawa R, Shirai T, Takesada Y and Fukushima S: Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogenesis model. Int J Cancer 55: 1011-1017, 1993.
18. Grubbs CJ, Juliana MM, Eto I, Casebolt T, Whitaker LM, Canfield GJ, Manczak M, Steele VE and Kelloff GJ: Chemoprevention by indomethacin of Nbutyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors. Anticancer Res 13: 33-36, 1993.
19. Moon R, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF and Sigman CC: Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis 14: 1487-1489, 1993.
20. Knapp DW, Richardson RC, Bottoms GD, Teclaw R and Chan TC: Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 29: 214-218, 1992.
21. Knapp DW, Richardson RC, Chan TC, Bottoms GD, Widmer WR, DeNicola DB, Teclaw R, Bonney PL and Kuczek T: Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 8: 273-278, 1994.
22. Khoo NK, Chan FP, Saarloos MN and Lala PK: Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclooxygenase inhibitors alone or in combination with IL-2. Clin Exp Metastasis 10: 239-252, 1992.
23. Khoo NK, Chan FP, Saarloos MN and Lala PK: Immunotherapy of metastases with ibuprofen and IL-2. Cancer Res 31: A1628, 1990.
24. Lala PK and Parhar RS: Eradication of spontaneous and experimental adenocarcinoma metastasis with chronic indomethacin and intermittent IL-2 therapy. Int J Cancer 54: 677-684, 1993.
25. Zhang S-Z and Fulton AM: Prostaglandin E2 receptor modulation affects tumor cell adhesion to laminin. J Cell Physiol 149: 208-213, 1991.
26. Waymack JP, Flescher E, Venkatraman J, Fernandas G, Gusman RF, Yurt RW, Mason AD and Pruitt BA: Effect of prostaglandin E in multiple experimental models. VIII. Effect on host response to metastatic tumor. J Surg Oncol 48: 239-245, 1991.
27. 2 receptor in mammary tumor metastasis. Cancer Res. 51: 2047-2050, 1991.
28. Young MRI, Lozano Y, Djorjevic A and Maier GD: Protein phosphatases limit tumor motility. Int J Cancer 55: 1036-1041, 1993.
29. 2 with more aggressive tumor behavior. Invasion and Metastasis 11: 48-57, 1991.
30. Lee PP and Ip MM: Regulation of proliferation of mammary tumor cells by inhibitors 31, 1992.
31. Willett LR, Carson JL and Strom BL: Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs. Drug Safety 10: 170-181, 1994.